SCHEMBL20122899

SCHEMBL20122899

CCn1c2c(-c3cccc(N4CCOCC4)c3)cc(Cl)cc2c2ccnc(C)c21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JMJD6 Q6NYC1 1/20 0.43
CAMK2D Q13557 1/20 0.42
METAP2 P50579 1/20 0.41
MAPK8 P45983 2/20 0.38
MAPK10 P53779 2/20 0.38
HSP90AA1 P07900 1/20 0.38
HSP90AB1 P08238 1/20 0.38
RPS6KA3 P51812 1/20 0.38
STK4 Q13043 1/20 0.38
STK3 Q13188 1/20 0.38
LRRK2 Q5S007 1/20 0.38
CHRM2 P08172 1/20 0.38
CHRM4 P08173 1/20 0.38
CHRM5 P08912 1/20 0.38
CHRM1 P11229 1/20 0.38
CHRM3 P20309 1/20 0.38
PIK3R2 O00459 3/20 0.37
ATR Q13535 1/20 0.37
ATRIP Q8WXE1 1/20 0.37
KCNH2 Q12809 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30664237 1.00 JMJD6 (0.43) JMJD6CAMK2DMETAP2MAPK8MAPK10
SCHEMBL20123008 0.85 PDE4B (0.46) HSP90AA1HSP90AB1LRRK2BRD4JAK2
SCHEMBL30664272 0.85 PDE4B (0.46) HSP90AA1HSP90AB1LRRK2BRD4JAK2
SCHEMBL30664339 0.83 CNR2 (0.52) ATRATRIPKCNH2PDE10A
SCHEMBL20122978 0.83 CNR2 (0.52) ATRATRIPKCNH2PDE10A
SCHEMBL30664218 0.78 CAMK2D (0.43) JMJD6CAMK2DMAPK8MAPK10RPS6KA3
SCHEMBL20122897 0.78 CAMK2D (0.43) JMJD6CAMK2DMAPK8MAPK10RPS6KA3
SCHEMBL20122862 0.78 PTGER4 (0.40) BRD4DYRK1A
SCHEMBL20122810 0.78 MAOA (0.49) MAPK8CHRM2CHRM1KCNH2
SCHEMBL20123023 0.78 DYRK1A (0.45) DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2021-09-28 US disclosed
EP-3792262-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2021-03-17 EP disclosed
EP-3535263-B1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI SA (FR) 2020-09-30 EP disclosed
EP-3318563-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2018-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 JMJD6 1321/4885CAMK2D 1580/4885METAP2 3515/4885
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 JMJD6 1321/4885CAMK2D 1580/4885METAP2 3515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.